Sponsors
The bill strengthens FDA and customs authority to keep unsafe imported drugs out of U.S. supply chains, but that broader power increases compliance burdens, risks restricting access to some legitimate imported therapies, and raises concerns about administrative discretion.
Patients and the public: FDA can more quickly exclude or impose controls on unsafe imported drugs beyond just controlled substances, improving protection from dangerous or adulterated products.
FDA and HHS staff and healthcare providers: The bill clarifies the chain of authority by explicitly including the CBER Director (or designated senior officials), reducing decision-making ambiguity for biologics-related admissibility orders.
Customs/Treasury and state enforcement: Import admissibility language is aligned so Customs and Treasury can act on orders covering drugs generally, improving consistency and effectiveness of enforcement against inadmissible imported products.
Importers and some drug suppliers: The bill expands regulatory reach, meaning more products could be detained or excluded at the border, raising compliance costs and causing shipment delays for businesses and health systems.
Patients who rely on niche or imported therapies: Increased detention or exclusion of a broader set of drugs could reduce access or slow availability of certain treatments.
Healthcare providers and small businesses: Broader, less-specific statutory wording increases the risk of regulatory overreach and administrative discretion, raising due-process and rights concerns for legally distributed but controversial products.
Based on analysis of 2 sections of legislative text.
Replaces “controlled substances” with “drug” in specified FD&C provisions and adds CBER leadership to an import-admissibility cross-reference, broadening statutory coverage.
Amends parts of the Federal Food, Drug, and Cosmetic Act to broaden certain provisions that previously applied only to “controlled substances” so they apply to all “drugs,” and updates an import-admissibility cross-reference to explicitly include the Director of the Center for Biologics Evaluation and Research (or senior officials). The change makes the statutory language broader and aligns import rules and enforcement references with CBER authority. The bill is a targeted statutory clarification and expansion of scope rather than a funding or program-creation measure. It does not authorize new spending, change tax law, or create new federal programs; it adjusts terminology and cross-references to affect how the FDA (including CBER) and customs authorities apply existing provisions to a wider set of products described as “drugs.”
Introduced March 18, 2026 by Maxine Dexter · Last progress March 18, 2026